Related Experiment Video
Updated: Jan 17, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children
Aisa Longnecker1, Cristina M Foschi2, Valerie M Carlberg2
1Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
None:
Spesolimab is an IL-36 receptor monoclonal antibody antagonist approved for generalized pustular psoriasis in patients 12 years and older. While it has demonstrated promising results in this population, there is limited literature exploring spesolimab efficacy and dosing in younger patients. We report the cases of a 5-year-old female with generalized pustular psoriasis in the setting of autosomal recessive deficiency of interleukin-36 receptor antagonist (DITRA) as well as a 6-year-old female with generalized pustular psoriasis of unknown genetic status, both successfully treated with spesolimab.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
iPS Cell Differentiation
